Company profile: Vanda Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of biopharmaceutical therapies focused on central nervous system disorders, developing and commercializing innovative products through clinical and commercial stage programs, including HETLIOZAccess: an expanded access program for Non-24-Hour Sleep-Wake Disorder (Non-24).
Products and services
- Global Development and Commercialization of Innovative Therapies: Develops and commercializes innovative therapies worldwide for central nervous system disorders, focused on addressing unmet needs through a coordinated, global-scale biopharmaceutical operation
- Clinical and Commercial Program Portfolio: Architects and advances clinical- and commercial-stage programs targeting central nervous system disorders to address unmet needs, structured around a rigorous, clinical-stage development pathway
- HETLIOZAccess: Expanded-access program that delivers treatment for Non-24-Hour Sleep-Wake Disorder (Non-24), supplying structured access to therapy for this circadian rhythm condition
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Vanda Pharmaceuticals
AlzProtect
HQ: United States
Website
- Description: Provider of biopharmaceutical drug candidates and clinical development for neurodegenerative diseases, including Alzheimer’s disease and orphan tauopathies such as Progressive Supranuclear Palsy. Offers AZP2006 with a unique mechanism targeting amyloid toxicity, Tau phosphorylation, oxidative stress, and neuroinflammation; conducts clinical trials and partners with pharmaceutical companies for marketing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AlzProtect company profile →
Muna Therapeutics
HQ: Denmark
Website
- Description: Provider of biopharmaceutical therapies and discovery platforms to slow or stop neurodegenerative diseases including Alzheimer’s, Parkinson’s, Frontotemporal Dementia, and Multiple Sclerosis. Programs include TREM2 agonism for early-stage Alzheimer’s, Kv1.3 blockade for Parkinson’s and MS, and MiND-MAP, an all-in-human target discovery and validation platform using single cell spatial multi-omics in patient samples.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Muna Therapeutics company profile →
LB Pharmaceuticals
HQ: United States
Website
- Description: Provider of development-stage CNS therapeutics focused on LB-102 (n-Methyl amisulpride), a modified amisulpride for schizophrenia, and clinical trials assessing its safety, efficacy, and pharmacokinetics. Also develops improved versions of CNS treatments widely used overseas but not FDA approved for commercialization in the United States.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full LB Pharmaceuticals company profile →
BioBDx
HQ: United States
Website
- Description: Provider of technologies for the diagnosis and management of neurological and psychiatric conditions, including the Quotient ADHD System, a tool that aids in the objective and accurate assessment of ADHD symptoms. Dedicated to delivering high-value information to physicians, parents and patients to guide personalized strategies and enhance quality of life for patients with ADHD.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioBDx company profile →
Addex Therapeutics
HQ: Switzerland
Website
- Description: Provider of clinical-stage, orally available small-molecule allosteric modulators. Pipeline includes ADX71149, an mGlu2 positive allosteric modulator in Phase 2 for epilepsy; dipraglurant, an mGlu5 negative allosteric modulator for post-stroke/TBI sensorimotor recovery; and GABAB PAM programs for substance use disorder (licensed to Indivior) and chronic cough.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Addex Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Vanda Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Vanda Pharmaceuticals
2.2 - Growth funds investing in similar companies to Vanda Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Vanda Pharmaceuticals
4.2 - Public trading comparable groups for Vanda Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →